Trials / Completed
CompletedNCT05169307
CPX-351 Real-World Effectiveness and Safety Study
CREST UK: CPX-351 Real-World Effectiveness and Safety Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 147 (actual)
- Sponsor
- Jazz Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
CPX-351 Real World Effectiveness and Safety Study (CREST UK) is a real-world evidence study designed to collect data on the potential benefits and/or risks of Vyxeos liposomal (liposomal daunorubicin/cytarabine; CPX-351) in routine clinical practice in the United Kingdom (UK).
Detailed description
This is a retrospective, non interventional, multi-centre, single arm, observational study designed to assess patients with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or acute myeloid leukaemia with myelodysplasia related changes (AML-MRC) who have been treated with Vyxeos liposomal (liposomal daunorubicin/cytarabine; CPX-351) in routine UK clinical practice and managed as per standard local practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CPX-351 | This is a retrospective, non-interventional, observational study. No study drug will be administered in this study. |
Timeline
- Start date
- 2022-01-14
- Primary completion
- 2022-06-15
- Completion
- 2022-06-15
- First posted
- 2021-12-23
- Last updated
- 2022-07-12
Locations
15 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05169307. Inclusion in this directory is not an endorsement.